公开(公告)号：EP3227262B1

公开(公告)日：2020-05-13

申请号：EP15864386.6

申请日：2015-12-02

申请人： Novira Therapeutics Inc.

发明人： CHEN, Austin ,  BRAVO, Yalda ,  STOCK, Nicholas ,  PEDRAM, Bijan ,  JACINTHO, Jason ,  CLARK, Ryan C. ,  TRUONG, Yen

IPC分类号： C07C323/62 ,  C07D213/81 ,  C07D295/185 ,  C07D305/06 ,  C07D305/08 ,  C07D307/10 ,  C07D307/18 ,  C07D309/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/337 ,  A61K31/351 ,  A61K31/44 ,  A61K31/4453 ,  A61K31/498 ,  A61K31/5375 ,  A61P31/12

公开(公告)号：EP3622955A1

公开(公告)日：2020-03-18

申请号：EP18194909.0

申请日：2018-09-17

申请人： Cheng, En-Che

发明人： Cheng, En-Che

IPC分类号： A61K31/4453 ,  A61K9/00 ,  A61P25/36 ,  A61P39/02 ,  A61P43/00

摘要： A purpose of Biperiden Hcl(10) is mainly to be provided to the patient to sooth brain disorder of the patient after the patient is treated with drug detoxification such that consciousness of the patient can be recovered to rapidly become normally physiological state.

公开(公告)号：EP3524240A1

公开(公告)日：2019-08-14

申请号：EP17858482.7

申请日：2017-10-05

申请人： Daiichi Sankyo Company, Limited

发明人： SONEDA, Tsuyoshi ,  NAKAMURA, Yuji ,  MATSUMOTO, Koji ,  TANAKA, Naomi ,  FUKUNAGA, Taichi

IPC分类号： A61K31/198 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4453 ,  A61P13/12 ,  A61P43/00 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/42 ,  C07C323/44 ,  C07D207/10 ,  C07D295/135 ,  C07D333/36

摘要： An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof:

wherein R 1 and R 2 are the same or different, and represent a C 1 -C 6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.

公开(公告)号：EP3030323B1

公开(公告)日：2019-04-24

申请号：EP14834451.8

申请日：2014-08-06

申请人： Imago Biosciences Inc.

发明人： MCCALL, John M. ,  RIENHOFF, Jr. Hugh, Young ,  CLARE, Michael

IPC分类号： C07D295/185 ,  C07C237/22 ,  C07D213/81 ,  C07D233/90 ,  C07D295/26 ,  A61K31/166 ,  A61K31/40 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/5375 ,  A61K31/54 ,  A61P35/00

公开(公告)号：EP3442514A1

公开(公告)日：2019-02-20

申请号：EP17719518.7

申请日：2017-04-11

申请人： Spedding Research Solutions ,  Université de Strasbourg ,  INSERM - Institut National de la Santé et de la Recherche Médicale

发明人： SPEDDING, Michael ,  HENRIQUES, Alexandre ,  LOEFFLER, Jean-Philippe

IPC分类号： A61K31/137 ,  A61K31/19 ,  A61K31/336 ,  A61K31/4025 ,  A61K31/4453 ,  A61P25/00

公开(公告)号：EP3386495A1

公开(公告)日：2018-10-17

申请号：EP16808622.1

申请日：2016-12-07

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université d'Aix Marseille ,  Centre National de la Recherche Scientifique (CNRS) ,  Université Paris Descartes ,  Assistance Publique-Hôpitaux de Paris (APHP)

发明人： NAQUET, Philippe ,  BATTEUX, Frédéric ,  KAVIAN, Niloufar

IPC分类号： A61K31/16 ,  A61K31/165 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4453 ,  A61K31/5375 ,  A61P37/00

CPC分类号： G01N33/573 ,  A61K31/16 ,  A61K31/165 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4453 ,  A61K31/5375 ,  G01N2333/98 ,  G01N2800/24

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of systemic sclerosis. In particular, the present invention relates to a method of treating systemic sclerosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of vanin-1 inhibitor.

公开(公告)号：EP3362056A1

公开(公告)日：2018-08-22

申请号：EP16784831.6

申请日：2016-10-14

申请人： Advanced Biodesign

发明人： CEYLAN, Ismail ,  QUASH, Gerry ,  PEREZ-ALEA, Mileidys ,  MARTIN, Guillaume

IPC分类号： A61K31/131 ,  A61K31/136 ,  A61K31/137 ,  A61K31/4453 ,  A61K31/5375 ,  A61P35/00 ,  G01N33/50

CPC分类号： A61K31/4453 ,  A61K31/131 ,  A61K31/136 ,  A61K31/137 ,  A61K31/255 ,  A61K31/5375 ,  A61P35/00 ,  A61P35/02 ,  G01N33/5011 ,  G01N33/574 ,  G01N33/68 ,  G01N33/84 ,  G01N2800/52

摘要： The present invention relates to the treatment of cancer in a subject, wherein cancer cells of said subject overproduce H2O2 and have a level of GSH below 0.5 nmol for 25 000 cells, with aminothiolester compounds or pharmaceutically acceptable salts thereof, in particular with S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, more particularly with 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate. It also relates to a method for selecting a subject suffering from a cancer and who will most likely benefit from a treatment with aminothiolester compounds or pharmaceutically acceptable salts thereof, in particular with S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, more particularly with 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate.

公开(公告)号：EP2865421B1

公开(公告)日：2018-05-30

申请号：EP13190536.6

申请日：2013-10-28

申请人： Albert-Ludwigs-Universität Freiburg

发明人： Schempp, Christoph ,  Woelfle, Ute

IPC分类号： A61P17/00 ,  A61P27/02 ,  A61P11/02 ,  A61K31/35 ,  A61K31/351 ,  A61K31/4453 ,  A61K36/76

CPC分类号： A61K31/4453 ,  A61K31/35 ,  A61K31/351 ,  A61K36/76

摘要： The invention relates to the use of ligands to a bitter taste receptor in the treatment of a pathological condition of an epithelial barrier such as skin disorders and disorders affecting the sinonasal mucosa and/or the eye.

公开(公告)号：EP1712242B1

公开(公告)日：2018-05-30

申请号：EP04807749.9

申请日：2004-12-24

申请人： Hagiwara, Masatoshi

发明人： HAGIWARA, Masatoshi ,  FUKUHARA, Takeshi ,  SUZUKI, Masaaki ,  HOSOYA, Takamitsu

IPC分类号： A61K45/00 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/55 ,  C07D295/12 ,  C07D295/06 ,  C07D213/81 ,  C07D213/82 ,  C07D213/83 ,  C07D401/12 ,  A61P31/12 ,  C12Q1/48

CPC分类号： A61K31/444 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377 ,  A61K31/55 ,  C07D211/14 ,  C07D213/81 ,  C07D213/82 ,  C07D401/12 ,  C12N15/1137 ,  Y02A50/385 ,  Y02A50/389 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467

摘要： The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.

公开(公告)号：EP3313399A2

公开(公告)日：2018-05-02

申请号：EP16818732.6

申请日：2016-06-29

申请人： NantBio, Inc.

发明人： RABIZADEH, Shahrooz ,  BUZKO, Oleksandr ,  WEINGARTEN, Paul ,  MCFARLANE, Heather ,  TSAI, Connie ,  BENZ, Stephen Charles ,  NIAZI, Kayvan ,  SOON-SHIONG, Patrick

IPC分类号： A61K31/415 ,  A61K31/4453 ,  A61K31/4465 ,  A61K31/538 ,  A61K45/06

CPC分类号： A61K31/4196 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/538 ,  A61K45/06 ,  A61P35/00 ,  A61K2300/00

摘要： Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.